QPPV.COM KNOWLEDGE ASSESSMENT

Pegfilgrastim: Pegylated G-CSF, Neutrophil Recovery and Pharmacovigilance

Test your understanding of the concepts covered by Pegfilgrastim: Pegylated G-CSF, Neutrophil Recovery and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why can comparing spontaneous-report counts between a reference pegfilgrastim product and a biosimilar be misleading without additional information?

Because spontaneous reports are never useful for biological medicines Because differences may reflect market share, reporting behaviour or stimulated reporting rather than a true difference in risk Because biosimilars cannot cause adverse reactions Because product identity is irrelevant once the active substance is known

Question 2 of 10 A chemotherapy patient receiving pegfilgrastim develops acute respiratory distress. Which pharmacovigilance approach is most appropriate?

Attribute the event to pegfilgrastim solely because it occurred during neutrophil recovery Assess ARDS while also investigating pneumonia, pulmonary embolism, fluid overload, transfusion-related injury and treatment toxicity Code only infection because respiratory symptoms in oncology patients are always infectious Exclude pegfilgrastim because pulmonary events are unrelated to G-CSF products

Question 3 of 10 Which statement most accurately describes biosimilarity in relation to pegfilgrastim?

A biosimilar must use an identical manufacturing process and identical device to the reference product A biosimilar is highly similar, with no clinically meaningful differences in quality, safety and efficacy based on the totality of evidence A biosimilar is a chemically unrelated medicine with the same clinical indication Biosimilarity removes the need to record the actual brand used

Question 4 of 10 Which feature most directly accounts for pegfilgrastim having longer systemic persistence than filgrastim?

Covalent polyethylene-glycol attachment that increases effective size and reduces renal filtration Irreversible activation of the G-CSF receptor Direct inhibition of chemotherapy metabolism in the liver Conversion into an intracellular storage form in neutrophils

Question 5 of 10 A patient develops febrile neutropenia despite a recorded pegfilgrastim prescription. Which initial assessment is most appropriate?

Conclude immediately that the product was ineffective Conclude immediately that a manufacturing defect caused the event Confirm the clinical definition, reconstruct actual exposure and timing, and assess regimen, disease and infection-related alternatives Exclude pegfilgrastim because prophylaxis always prevents febrile neutropenia

Question 6 of 10 Which data set would provide the strongest basis for interpreting a suspected pegfilgrastim-related leukocytosis?

A single high white-cell count with no clinical context Serial blood counts linked to chemotherapy and pegfilgrastim timing, with review of infection, corticosteroids and haematological disease The patient's age alone The product brand without any laboratory results

Question 7 of 10 A patient treated with pegfilgrastim develops fever, back pain and elevated inflammatory markers. Which evidence would most help evaluate possible aortitis?

A single temperature measurement without further investigation Imaging of the aorta and major branches, microbiological evaluation, treatment timing, recurrence and response to withdrawal or anti-inflammatory therapy The presence of bone pain in a previous chemotherapy cycle only A product complaint unrelated to the patient's administration

Question 8 of 10 Why is administration timing relative to cytotoxic chemotherapy a key element in assessing pegfilgrastim cases?

Timing determines whether pegfilgrastim is converted into filgrastim Administration too close to cytotoxic treatment may be biologically inappropriate and can affect effectiveness and safety interpretation Timing is relevant only for device complaints, not for clinical outcomes Pegfilgrastim has no relationship to the chemotherapy cycle once it is prescribed

Question 9 of 10 How should an adverse event following use outside the authorised indication generally be handled in pharmacovigilance?

It is not reportable because the use was outside the indication It should be assessed and reported under applicable rules, while clearly distinguishing the reported use from the authorised scope Off-label use automatically proves that the product caused the event The event should be attributed to chemotherapy without further review

Question 10 of 10 Why should aggregate surveillance for possible G-CSF-associated aortitis use more than one preferred event term?

Because a single term may miss related reports coded as arteritis or periaortic inflammation Because all inflammatory terms are automatically equivalent Because coding terms eliminate the need for medical review Because aortitis can only be detected through device complaint terminology

Pegfilgrastim: Pegylated G-CSF, Neutrophil Recovery and Pharmacovigilance

Cookie Settings